Trials / Completed
CompletedNCT00620061
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 439 (actual)
- Sponsor
- Sucampo Pharma Americas, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety and efficacy of lubiprostone administration in participants with opioid-induced bowel dysfunction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lubiprostone 24 | 24 mcg capsules for oral administration |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2008-02-21
- Last updated
- 2020-01-21
- Results posted
- 2019-12-30
Locations
123 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00620061. Inclusion in this directory is not an endorsement.